Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 318 results for eq-5d

  1. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

  2. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)

    Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

  3. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

    Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.

  4. Baricitinib for treating moderate to severe atopic dermatitis (TA681)

    Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.

  5. Technology appraisals - position statements

    dose standardisation: NICE position statement Our position on use of the EQ‑5D‑5L valuation set for England Participation in clinical...

  6. Technology appraisal position statements

    dose standardisation: NICE position statement Our position on use of the EQ‑5D‑5L valuation set for England Participation in clinical...

  7. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.

  8. Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

    Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.

  9. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.

  10. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

    Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.

  11. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....

  12. Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

  13. Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)

    Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.

  14. Siponimod for treating secondary progressive multiple sclerosis (TA656)

    Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.

  15. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.